Table 3.

The endogenous, peptide degradation process, described in the article, assumes a 10 minutes intravascular peptide half-life due to renal clearance and hepatic-enzymatic degradation. 40 mg (4 mL) of the peptide mixture (40,000 μg) was subcutaneously administered weekly. The time-distributed endogenous doses of the ADARM, DHSYQE, and KTGQF peptide mix are reflected below

	μg Peptides	Minutes	Hours	Days
Dilution:	40,000
½	20,000	10	0	0
¼	10,000	20	0	0
1/8	5,000	40	1	0
1/16	2,500	80	1	0
1/32	1,250	160	3	0
1/64	625	320	5	0
1/128	313	640	11	0
1/256	156	1,280	21	1
1/512	78	2,560	43	2
1/1,024	39	5,120	85	4
1/2,048	20	10,240	171	7
1/4,096	10	20,480	341	14
1/8,192	5	40,960	683	28
1/16,384	2	81,920	1,365	57
16.75 μg empirically tittered peptide mix needed to yield zero serum specific IgE level.

Depicted is the expected, 10 minute intravascular half-life of the PLP epitope-mimicking peptide ADARM and the MOG-mimicking peptides, DHSYQE, and KTGQF. The ongoing, endogenous loss is likely to be caused by renal clearance and enzymatic degradation. The infused peptides would, thereby, complex with and neutralize their corresponding epitope-specific IgE and non-IgE autoantibodies for a 1-2 weeks period. Absence of the specific autoantibodies would bring to a halt the related mast cell degranulation and neuropathology.